TDMS Study 92012-06 Pathology Tables
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
FINAL#1/MICE
Facility: Southern Research Institute
Chemical CAS #: 693-98-1
Lock Date: 10/16/01
Cage Range: All
Reasons For Removal: 25019 Moribund Sacrifice 25020 Natural Death
25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 2 3 4 4
Natural Death 2 3 2 1
Survivors
Terminal Sacrifice 46 42 42 45
Moribund Sacrifice 1
Natural Death 1
Animals Examined Microscopically 50 49 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (48) (48) (50)
Intestine Small, Duodenum (50) (49) (48) (49)
Carcinoma 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (50) (46) (48) (49)
Serosa, Histiocytic Sarcoma 1 (2%)
Liver (50) (49) (49) (50)
Hepatocellular Carcinoma 2 (4%)
Hepatocellular Adenoma 2 (4%) 3 (6%) 6 (12%) 9 (18%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pancreas (50) (49) (48) (50)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (49) (49) (49)
Stomach, Forestomach (50) (49) (49) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%) 2 (4%)
Squamous Cell Papilloma, Multiple 1 (2%)
Stomach, Glandular (50) (49) (48) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (49) (50)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Medulla (50) (49) (49) (50)
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (50) (48) (48) (50)
Adenoma 1 (2%)
Pituitary Gland (50) (49) (47) (49)
Pars Distalis, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (49) (48) (48) (50)
Unilateral, Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (49) (48)
Cystadenoma 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%) 1 (2%)
Uterus (50) (49) (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Polyp Stromal 2 (4%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (48) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (12) (6) (8) (9)
Lymph Node, Mandibular (48) (48) (46) (48)
Lymph Node, Mesenteric (48) (48) (47) (48)
Histiocytic Sarcoma 1 (2%)
Spleen (50) (49) (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (50) (48) (48) (50)
Page 3
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (49) (50)
Carcinoma 1 (2%) 2 (4%)
Skin (50) (49) (49) (50)
Basal Cell Carcinoma 1 (2%)
Keratoacanthoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 3 (6%) 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (49) (50)
Osteoma 1 (2%)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (49) (50)
Cranial Nerve, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (49) (50)
Alveolar/Bronchiolar Adenoma 4 (8%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (49) (49) (50)
Adenoma 3 (6%) 2 (4%) 6 (12%) 6 (12%)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (49) (50)
Urinary Bladder (50) (49) (49) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(49) *(49) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 6 (12%) 8 (16%) 6 (12%) 8 (16%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 23 20 23 29
Total Primary Neoplasms 28 28 30 36
Total Animals with Benign Neoplasms 13 12 14 20
Total Benign Neoplasms 14 15 15 22
Total Animals with Malignant Neoplasms 12 12 15 14
Total Malignant Neoplasms 14 13 15 14
Total Animals with Metastatic Neoplasms
Total Metastatic Neoplasm
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 4 1 5 5
Natural Death 3 3 9 5
Survivors
Terminal Sacrifice 43 46 36 40
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (49) (49) (47) (50)
Intestine Small, Duodenum (49) (49) (45) (50)
Polyp Adenomatous 1 (2%) 1 (2%)
Intestine Small, Jejunum (50) (49) (46) (50)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Liver (50) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%)
Hepatocellular Carcinoma 4 (8%) 5 (10%) 8 (16%) 5 (10%)
Hepatocellular Carcinoma, Multiple 3 (6%) 6 (12%) 1 (2%)
Hepatocellular Adenoma 5 (10%) 11 (22%) 9 (18%) 15 (30%)
Hepatocellular Adenoma, Multiple 2 (4%) 3 (6%) 4 (8%) 3 (6%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Liposarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Pancreas (50) (50) (49) (50)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (49) (50) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Liposarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Capsule, Adenoma 2 (4%) 1 (2%)
Islets, Pancreatic (50) (50) (49) (50)
Adenoma 1 (2%)
Pituitary Gland (49) (48) (48) (50)
Thyroid Gland (50) (50) (50) (50)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
Unilateral, Follicular Cell, Adenoma 6 (12%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Preputial Gland (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Testes (50) (50) (50) (50)
Sertoli Cell Tumor Malignant 1 (2%)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (2) (3) (1)
Inguinal, Histiocytic Sarcoma 1 (50%)
Inguinal, Osteosarcoma, Metastatic, Bone 1 (100%)
Mediastinal, Osteosarcoma, Metastatic, Bone 1 (100%)
Lymph Node, Mandibular (48) (46) (45) (50)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (47) (47) (46) (48)
Histiocytic Sarcoma 1 (2%)
Spleen (50) (50) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Page 8
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Thymus (47) (46) (46) (47)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Schwannoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Liposarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Osteoma 1 (2%)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1) (2)
Hemangiosarcoma 1 (100%)
Liposarcoma, Metastatic, Uncertain Primary
Site 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 11 (22%) 7 (14%) 6 (12%) 4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 2 (4%) 4 (8%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Kidney 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 6 (12%) 2 (4%)
Page 9
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Liposarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (48) (50)
Adenoma 9 (18%) 6 (12%) 5 (10%) 3 (6%)
Carcinoma 1 (2%) 3 (6%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Liposarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%) 1 (2%)
Urinary Bladder (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leukemia Granulocytic 1 (2%)
Lymphoma Malignant 2 (4%) 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 02/25/03
Route: DOSED FEED Time: 07:34:38
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 32 34 34 38
Total Primary Neoplasms 50 53 52 56
Total Animals with Benign Neoplasms 23 25 24 30
Total Benign Neoplasms 28 32 27 39
Total Animals with Malignant Neoplasms 20 16 21 14
Total Malignant Neoplasms 22 21 25 17
Total Animals with Metastatic Neoplasms 1 3 7 5
Total Metastatic Neoplasm 1 3 7 14
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------